The Food and Drug Administration said Thursday that the longstanding shortage of Eli Lilly’s weight-loss drug Zepbound and ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 480.21% and ...

In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin and the rest of the state as it continues to grow. Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...

With Eli Lilly's diabetes and obesity products Mounjaro and Zepbound booming in popularity, the drugmaker finds itself in a welcome predicament: What to do with all that cash? One answer ...

Eli Lilly and Novo Nordisk dominate the market ... Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though ...

Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.' ...

Eli Lilly is spending another $3 billion to bulk ... demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion ...